1. Search Result
Search Result
Results for "

CD40/CD40L

" in MedChemExpress (MCE) Product Catalog:

23

Inhibitors & Agonists

1

Peptides

14

Inhibitory Antibodies

41

Recombinant Proteins

3

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99315

    BG 9588; Anti-Human CD40L Recombinant Antibody; Hu5c8

    TNF Receptor Inflammation/Immunology
    Ruplizumab (BG 9588) is a humanized anti-CD40L IgG1κ monoclonal antibody. By binding to CD40L, Ruplizumab blocks its interaction with the CD40 receptor, inhibits T-B cell costimulatory signals, and mediates the depletion of activated T cells via the Fc segment. Ruplizumab has immunosuppressive effects. Ruplizumab can be used in the study of systemic lupus erythematosus, organ transplant rejection, and autoimmune diseases. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
    Ruplizumab
  • HY-P990133

    TNF Receptor Inflammation/Immunology
    Anti-Monkey/Human CD40L/CD154 Antibody (5C8) is a mouse-derived IgG2a type antibody inhibitor, targeting to monkey/human CD40L/CD154. Anti-Monkey/Human CD40L/CD154 Antibody (5C8) blocks the interactionbetween CD154 and CD40. Anti-Monkey/Human CD40L/CD154 Antibody (5C8) can be used for the researches of inflammation and immunology, such as colitis and transplant .
    Anti-Monkey/Human CD40L/CD154 Antibody (5C8)
  • HY-122663A

    TNF Receptor Apoptosis Metabolic Disease
    BIO8898 is a potent CD40-CD154 inhibitor. BIO8898 inhibits soluble CD40L binding to CD40-Ig with an IC50 value of 25 µM. BIO8898 inhibits CD40L-induced apoptosis .
    BIO8898
  • HY-P990134

    TNF Receptor IFNAR Inflammation/Immunology Cancer
    Anti-Mouse CD40L/CD154 Antibody (MR-1) is an anti-mouse CD40L/CD154 IgG monoclonal antibody. Anti-Mouse CD40L/CD154 Antibody (MR-1) reduces the expression of IFN signaling pathway and lowers the level of IFN-β. Anti-Mouse CD40L/CD154 Antibody (MR-1) can prolong the survival time of transplants. Anti-Mouse CD40L/CD154 Antibody (MR-1) can be used for research on cancer, inflammation conditions and xenotransplantation such as pancreatic cancer and autoimmune cholangitis .
    Anti-Mouse CD40L/CD154 Antibody (MR-1)
  • HY-P99842A

    TNF Receptor Inflammation/Immunology
    Dapirolizumab is a monoclonal antibodi against CD40 ligand. Dapirolizumab targets CD40L, blocks its interaction with CD40 receptors, and inhibits adaptive immune activation. Dapirolizumab attenuates systemic lupus erythematosus .
    Dapirolizumab
  • HY-P990269

    TNF Receptor Others
    Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse CD40L/CD154.
    Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1)
  • HY-P99257

    ASKP 1240

    TNF Receptor Inflammation/Immunology
    Bleselumab (ASKP 1240) is a human anti-CD40 monoclonal antibody (mAb). Bleselumab binds to human CD40 with high affinity (Kd: 0.24 nM). Bleselumab inhibits immune responses by blocking the interaction of CD40 with its ligand CD40L. Bleselumab prevents organ transplant rejection .
    Bleselumab
  • HY-P99321

    BMS 224819; Chi220; Anti-Human CD40 Recombinant Antibody

    TNF Receptor Inflammation/Immunology Cancer
    Teneliximab (BMS-224819) is a chimeric monoclonal antibody, blocks the CD40-CD40L interaction. Teneliximab (BMS-224819) has partial agonist activity resulting in some signaling through CD40 and peripheral B cell depletion .
    Teneliximab
  • HY-P990270

    TNF Receptor Others
    Anti-Mouse CD40L/CD154 (D265A) Antibody (MR-1) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse CD40L/CD154.
    Anti-Mouse CD40L/CD154 (D265A) Antibody (MR-1)
  • HY-P10399

    Mouse KGYY15; KGYY15 peptide

    TNF Receptor Metabolic Disease
    KGYY15 (Mouse KGYY15) is a CD40 targeting peptide, which weakly inhibits the CD40-CD40L interaction with IC50 of more than 1mM. KGYY15 activates 33% NF-κB pathway at 100 μM .
    KGYY15
  • HY-P990083

    TNF Receptor Cancer
    Tegoprubart is a monoclonal antibody directed against CD40 ligand (CD40L), a key mediator of costimulation. Inhibition of CD40L reduces cellular and antibody-mediated immunity and creates a more tolerant immune environment. Tegoprubart was demonstrated to have in vivo efficacy in transplantation animal models.
    Tegoprubart
  • HY-P99625

    SAR441344; INX-021

    TNF Receptor Metabolic Disease Inflammation/Immunology
    Frexalimab (SAR441344) is a second-generation monoclonal antibody targeting the CD40 ligand (CD40L) with a good safety profile. Frexalimab inhibits the binding between CD40 and CD40L to modulate immune response. Frexalimab is likely to help prevent the process of β-cell destruction. Frexalimab is proming for multiple sclerosis, lupus erythematosus, Sj gren’s syndrome and type I diabetes research .
    Frexalimab
  • HY-154821

    TNF Receptor Inflammation/Immunology
    DRI-C21041 is a CD40/CD40L interaction inhibitor, with an IC50 of 0.31 μM. DRI-C21041 inhibits the immune response induced by alloantigen .
    DRI-C21041
  • HY-154821A

    TNF Receptor Inflammation/Immunology
    DRI-C21041 DIEA is a CD40/CD40L interaction inhibitor, with an IC50 of 0.31 μM. DRI-C21041 DIEA inhibits the immune response induced by alloantigen .
    DRI-C21041 (DIEA)
  • HY-P99167

    HCD122

    TNF Receptor Cancer
    Lucatumumab (HCD122) is a fully human anti-CD40 antagonist monoclonal antibody, which blocks CD40/CD40L-mediated signaling. Lucatumumab efficiently mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and clearance of tumor cells, can be used for refractory lymphomas, CLL and multiple myeloma research .
    Lucatumumab
  • HY-154822

    TNF Receptor Inflammation/Immunology
    DRI-C25441 is a potent blocker of CD40 and CD40L interaction, with an IC50 of 0.36 μM. DRI-C25441 can inhibit the immune response induced by alloantigen .
    DRI-C25441
  • HY-120323
    DRI-C21045
    1 Publications Verification

    TNF Receptor Inflammation/Immunology
    DRI-C21045 (compound 10) is a potent and selective inhibitor of the CD40-CD40L costimulatory protein-protein interaction (PPI) with an IC50 of 0.17 μM. DRI-C21045 shows concentration-dependent inhibition of the activation of NF-κB and B cell proliferation all induced by CD40L with IC50s of 17.1 μM and 4.5 μM, respectively .
    DRI-C21045
  • HY-P99325

    IDEC-131; Anti-Human CD40 ligand Recombinant Antibody

    TNF Receptor Inflammation/Immunology
    Toralizumab (IDEC-131) is a humanized monoclonal antibody (mAb) against CD40L (CD154) comprised of human gamma 1 heavy chains and human kappa light chains. Toralizumab binds specifically to human CD40L on T cells, thereby preventing CD40 signaling. Toralizumab is an immunosuppressive agent. Toralizumab can lead to increased thrombosis. Toralizumab can be studied in research for diseases such as multiple sclerosis, systemic lupus erythematosus (SLE), and Crohn’s disease .
    Toralizumab
  • HY-P991510

    TNF Receptor Cancer
    CDX-1140 is a human IgG2 CD40 agonist antibody. CDX-1140 activates dendritic cells (DCs) and B cells and drives NF-kB stimulation in a CD40-expressing reporter cell line. CDX-1140 is independent of FcR binding and synergistic with native CD40L signaling. CDX-1140 has both direct and immune-mediated anti-tumor activity. CDX-1140 can be used for the study of lymphoma cancer and solid tumors .
    CDX-1140
  • HY-16668
    Tyrphostin A1
    1 Publications Verification

    Tyrphostin 1; AG9

    Interleukin Related Inflammation/Immunology
    Tyrphostin A1(AG9) inhibits CD40L-stimulated IL-12 production in macrophage cultures and antigen-induced generation of Th1 cells.
    Tyrphostin A1
  • HY-16668R

    Interleukin Related Inflammation/Immunology
    Tyrphostin A1 (Standard) is the analytical standard of Tyrphostin A1. This product is intended for research and analytical applications. Tyrphostin A1 (AG9) can inhibit CD40L-stimulated IL-12 production and antigen-induced Th1 cell production in macrophage culture.
    Tyrphostin A1 (Standard)
  • HY-P99701

    BMS-986004

    TNF Receptor Inflammation/Immunology
    Letolizumab (BMS-986004) is a monoclonal antibody targeting CD40L, which is produced to express mutant IgG1 lacking effector function, including Fc binding and complement fixation. Letolizumab reduces rejection, thromboembolism and prolongs the survival time .
    Letolizumab
  • HY-120471

    PI3K Inflammation/Immunology
    AM-0687 is a selective inhibitor for PI3Kδ with an IC50 of 2.9 nM. AM-0687 decreases the levels of IgG and IgM specific antibodies, inhibits the anti-IgM/CD40L-induced proliferation of human B cell (IC50=0.8 nM) and the phosphorylation of AKT (IC50=0.7 nM), and exhibits anti-inflammatory efficacy .
    AM-0687

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: